Vol 5, Issue 3, 2018

Research Article



ISSN 2349-7041

MATHEMATICAL PROCESSING FOR SIMULTANEOUS SPECTROPHOTOMETRIC DETERMINATION OF CYCLOPENTOLATE AND PHENYLEPHRINE IN THEIR BINARY MIXTURE

MOHAMMED WAFAA NASSAR, KHALID A.M. ATTIA, RAGAB A. SAID, AHMED EL-OLEMY & MOHAMED A. HASAN*

Pharmaceutical analytical Chemistry Department, Faculty of Pharmacy, Al-Azhar University, 11751 Nasr City, Cairo, Egypt.

Email: mohamedabdallah_87@yahoo.com, mohamedabdallah_87@azhar.edu.eg

ABSTRACT

Objective: Development and validation of three simple, accurate, selective and and low cost spectrophotometric methods for simultaneous determination of cyclopentolate hydrochloride (CLO) and phenylephrine hydrochloride (PHE) in their binary mixture without need of any preseparation step or sophisticated instruments. **Methods:** These methods are (I) area under the curve method using two ranges of wavelengths (255 - 260) and (271 - 275) nm. (II) Q-analysis method using two wavelengths 281.2 nm (iso-absorptive point) and 291 nm. (III) bivariate method using two wavelengths 285 and 270 nm choosen according to Kaiser method to calculate the sensitivity matrices of different wavelengths. **Results:** Calibration graphs were established in the range of 10-130 μ g/ml for both drugs with good correlation coefficients. **Conclusion:** All the proposed methods were validated and successfully applied for simultaneous determination of cyclopentolate hydrochloride (CLO) and phenylephrine hydrochloride (PHE) in their bulk powder and pharmaceutical preparation Cyclophrine® eye drops. The obtained results were statistically compared with those of the reported method by applying student's t-test and F-test at 95 % confidence level and no significant difference was observed regarding accuracy and precision.

Keywords: cyclopentolate hydrochloride; phenylephrine hydrochloride; enriching technique; area under the curve; Q-analysis; bivariate; Kaiser method and sensitivity matrices.

INTRODUCTION

Cyclopentolate hydrochloride is 2-(dimethylamino)ethyl-(2RS)-(1hydroxycyclopentyl)phenyl acetate hydrochloride, figure 1. It is official in British and United states pharmacopoeias [1,2] which is considered as antimuscarinic drug with actions similar to those of atropine and is used as eye drops to produce mydriasis and cycloplegia for ophthalmic diagnostic procedures and for the treatment of uveitis and iritis.[3] Phenylephrine hydrochloride is (1R)-1-(3-hydroxyphenyl)-2-(methylamino) ethanol hydrochloride, figure (2). It is official in British and United states pharmacopoeias $^{[1,2]}$ which is considered as selective α_1 -adrenergic receptor agonist used primarily as a vasoconstrictor, decongestant and as mydriatic agent. Combination of cyclopentolate hydrochloride and phenylephrine hydrochloride is used as an ophthalmic solution to produce mydriasis and the amount of mydriasis produced by this combination is greater than that produced by either agent alone [3].

Literature survey reveals few methods for determination of cyclopentolate hydrochloride alone in pharmaceutical preparations including two colorimetric methods [4,5], spectrofluorimetric method [5], electrochemical method [6], gas chromatographic method [7] and HPLC method [8]. Also literature survey reveals few methods for determination of phenylephrine hydrochloride alone in pharmaceutical preparations including spectrophotometric methods [9-13], electrochemical methods [14-19], and HPLC methods [20-22].

Reviewing the literature on the simultaneous determination of cyclopentolate hydrochloride and phenylephrine hydrochloride in their binary mixture revealed only two reported separation techniques including thin layer chromatography and HPLC methods [23] and the lack of any spectrophotometric methods for the simultaneous determination of the two drugs in their binary mixture. The aim of this work is to develop and validate simple, sensitive, selective and cost effective spectrophotometric methods for the simultaneous determination of cyclopentolate hydrochloride and phenylephrine hydrochloride in their binary mixture without preliminary separation.




Fig. 1 Structural formula of cyclopentolate hydrochloride.




Fig. 2: Structural formula of phenylephrine hydrochloride.

Theory

Theory of area under the curve method:

Area under curve method utilizes two wavelength ranges. From the overlain spectra of both drugs the area under curve is determined at both the selected analytical wavelength ranges.

Within the above selected wavelength ranges, the area under curve was determined for both the drugs and analysis was performed using "Cramer's Rule" and "Matrix Method" [24].

Consider a binary mixture consisting of two components X and Y, from the spectra of two components, following information is obtained:

- **AUC** $_{\lambda_{1-\lambda_{2}}}^{X}$: area under curve for component **X** at the wavelength range $\lambda_{1} \lambda_{2}$.
- $AUC_{\lambda_{3-\lambda_{4}}}^{X}$: area under curve for component X at the wavelength range $\lambda_{3} \lambda_{4}$.
- $AUC^{Y}_{\lambda 1-\lambda 2}$: area under curve for component Y at the wavelength range $\lambda_1 \lambda_2$.
- $AUC_{\lambda_{3-\lambda_{4}}}^{Y}$: area under curve for component *Y* at the wavelength range $\lambda_{3} \lambda_{4}$.

The total area under the curve of a mixture at a particular wavelength range is equal to the sum of area under curve of the individual components at same wavelength range. The area under curve of the mixture containing component X and Y can be given as follows:

$$AUC_{\lambda 1-\lambda 2} = AUC_{\lambda 1-\lambda 2}^{X} + AUC_{\lambda 1-\lambda 2}^{Y}$$
(1)

$$AUC_{\lambda 3-\lambda 4} = AUC^{X}_{\lambda 3-\lambda 4} + AUC^{Y}_{\lambda 3-\lambda 4}$$
⁽²⁾

Now the above equations can also be written as follows:

$$AUC_{\lambda 1-\lambda 2} = a^{X}{}_{\lambda 1-\lambda 2} bC^{X} + a^{Y}{}_{\lambda 1-\lambda 2} bC^{Y}$$
(3)
$$AUC_{\lambda 3-\lambda 4} = a^{X}{}_{\lambda 3-\lambda 4} bC^{X} + a^{Y}{}_{\lambda 3-\lambda 4} bC^{Y}$$
(4)

Where,

$$a_{\lambda 1-\lambda 2} = absorptivity at (\lambda 1 - \lambda 2)$$

$$a_{\lambda 3-\lambda 4} = absorptivity at (\lambda 3 - \lambda 4)$$

By applying "Cramer's Rule" and "Matrix Method", the concentration of component *X* and component *Y* can be determined as follows:

$$C^{X} = \frac{\left(a^{Y}_{\lambda_{1}-\lambda_{2}} AUC_{\lambda_{3}-\lambda_{4}}\right) - \left(a^{Y}_{\lambda_{3}-\lambda_{4}} AUC_{\lambda_{1}-\lambda_{2}}\right)}{\left(a^{Y}_{\lambda_{1}-\lambda_{2}} a^{X}_{\lambda_{3}-\lambda_{4}}\right) - \left(a^{Y}_{\lambda_{3}-\lambda_{4}} a^{X}_{\lambda_{1}-\lambda_{2}}\right)}$$
(5)

$$C^{Y} = \frac{(a^{X}_{\lambda_{1-\lambda_{2}}} AUC_{\lambda_{3-\lambda_{4}}}) - (a^{X}_{\lambda_{3-\lambda_{4}}} AUC_{\lambda_{1-\lambda_{2}}})}{(a^{Y}_{\lambda_{1-\lambda_{2}}} a^{X}_{\lambda_{3-\lambda_{4}}}) - (a^{Y}_{\lambda_{3-\lambda_{4}}} a^{X}_{\lambda_{1-\lambda_{2}}})}$$
(6)

Theory of Q-analysis method:

Suppose the first drug is *X* and the second is *Y*. According to Q-absorbance ratio method, uses the ratio of absorption at two selected wavelengths, one is at λ_{iso} and other being the λ_{max} of one of the two components [25,26].

Two equations were constructed as described below, using the relationship $a_{x1}=a_{y1}$ and L=1. Equations are;

At
$$\lambda_1 : A_1 = a_{x1}C_x + a_{y1}C_y$$
 (because $ax_1 = ay_1$)
(1)

$$At \lambda_2 : A_2 - a_{x2}C_x + a_{y2}C_y$$
(2)

Dividing equation (2) by (1), we get;

$$A_2/A_1 - (a_{x2}C_x + a_{y2}C_y)/(a_{x1}C_x + a_{y1}C_y)$$
(3)

$$\label{eq:constraint} \begin{split} \mathcal{C}_x/(\mathcal{C}_x+\mathcal{C}_y) &= F_x \quad \mathcal{C}_y/(\mathcal{C}_x+\mathcal{C}_y)-F_y \\ \text{Let} & \& \end{split}$$

Dividing equation (3) by C_x+C_y , we get;

$$A_2/A_1 - (a_{x2}F_x + a_{y2}F_y)/(a_{x1}F_x + a_{y1}F_y)$$

$$F_y = 1$$
 F_x
,But
 $A_2/A_1 = (a_{x2}F_x + a_{y2} - a_{y2}F_x)/a_{x1}$ (4)

$$a_{x1} - a_{y1}$$
, Because
$$A_2/A_1 = (a_{x2}F_x/a_{x1}) - (a_{y2}F_x/a_{y1}) + (a_{y2}/a_{y1})$$

$$a_{x2}/a_{x1} - Q_x - a_{y2}/a_{y1} - Q_y - A_2/A_1 = Q_M$$
Let
$$a_x - F_x Q_x - F_x Q_y + Q_y$$
So,
$$F_x = (Q_M - Q_y)/(Q_x - Q_y)$$
(5)

This equation gives the fraction of mixture that determine the absolute concentration of X and Y.

$$C_{s}/(C_{s}+C_{y}) = (A_{2}/A_{1}) - (a_{y2}/a_{y1})/(a_{s2}/a_{s1}) - (a_{y2}/a_{y1})$$
(6)

Both equation (5) & (6) gives the fraction, rather than the concentration of X and consequently of Y in the mixture in the term of absolute ratio. As, these are independent of concentration only approximate rather than accurate.

If the absolute concentration of X & Y than rearrange equation (1), we get;

$$C_x + C_y - A_1/a_{x1} \tag{7}$$

0)

From equations (6) & (7), we get;

 $C_{1}(A_{1}|a_{1}) = (0_{11} - 0_{1})/(0_{1})$

$$C_{x} = \{(Q_{M} - Q_{y})/(Q_{x} - Q_{y})\} \times (A_{1}/a_{x1})$$

$$C_{y} = \{(Q_{M} - Q_{x})/(Q_{y} - Q_{x})\} \times (A_{1}/a_{y1})$$

$$\& \qquad (9)$$

Finally equations (8) & (9) gives the absolute concentration value of drug $X \otimes Y$.

Theory of bivariate method:

 The principle of bivariate calibration is the measurement of two components (*X* and *Y*) at two selected wavelengths (λ₁ and λ₂) to obtain two equations:

 $A_{XY1} = m_{X1}C_X + m_{Y1}C_Y + e_{XY1}(1)$

 $A_{XY2} = m_{X2}C_X + m_{Y2}C_Y + e_{XY2}$ (2)

• The resolution of such equations set allows the evaluation of C_x and C_y values:

$$C_{X} = (A_{XY1} - e_{XY1} - m_{Y1}C_{Y}) / m_{X1}$$
(3)

 $C_{Y} = [m_{X2} (A_{XY1} - e_{XY1}) + m_{X1} (e_{XY2} - A_{XY2})] / m_{X2}m_{Y1} - m_{X1}m_{Y2}$ (4)

Where:

- C_X, C_Y are the concentration of component X, component Y.
- m_{X1} , m_{X2} are the slope values of component X at λ_1 , λ_2 .
- m_{Y1} , m_{Y2} are the slope values of component Y at λ_1 , λ_2 .
- A_{XY1} , A_{XY2} are the absorbance values of the binary mixture at λ_1 , λ_2 .
- e_{XY1} , e_{XY2} are the sum of the intercepts of components X, Y at λ_1 , λ_2 .
- This simple mathematic algorithm allows the resolution of the two components by measuring the absorbance of their mixture at the two selected wavelengths and using the parameters of the linear regression functions evaluated individually for each component at the same wavelengths [27].
- According to Kaiser method, [28] the slope values of the linear regression equations for both components at different wavelengths were used to calculate the sensitivity matrices (K)

to find out the optimum pair of wavelengths (highest matrix value) at which the binary mixture was determined.

K=	mx1 my	1		
	mx2 my		(5)

EXPERIMENTAL

Instruments

Shimadzu UV-Visible 1800 Spectrophotometer, (Tokyo, Japan), equipped with 10 mm matched quartz cells. The bundled software, UV-Probe personal spectroscopy software version 2.21 (Shimadzu).

Materials and solvents

- Pure cyclopentolate hydrochloride (99.45%) and phenylephrine hydrochloride (99.70%) were kindly supplied by Kahira pharmaceutical and chemical industrial company – Cairo – Egypt.
- Cyclophrine[®] eye drops: each (1ml) claimed to contain 10 mg of cyclopentolate hydrochloride and 100 mg of phenylephrine hydrochloride (batch number: 1660119), manufactured by Kahira pharmaceutical and chemical industrial company – Cairo – Egypt, purchased from local market.
- Methanol, analytical grade (Sigma–Aldrich, Germany).

Standard solutions

Cyclopentolate hydrochloride and phenylephrine hydrochloride standard solutions (each, 1 mg/ml), were prepared by dissolving 100 mg of the drugs powder separately in 50 ml of methanol into two 100-ml volumetric flasks and then completing to volume with the same solvent.

Procedures

General procedure

Different aliquots equivalent to (0.1-1.3 mg) of cyclopentolate hydrochloride and phenylephrine hydrochloride were accurately transferred from their standard solutions (1 mg/ml) into two separate series of 10-ml volumetric flasks and completed to volume with methanol. The absorption spectra (from 200 to 300 nm) of these solutions were recorded using methanol as a blank.

For area under the curve method: Area under the curves obtained from the scanned spectra over the ranges of wavelengths (255 - 260) and (271 - 275) nm were recorded and then the corresponding regression equations were computed for both cyclopentolate hydrochloride and phenylephrine hydrochloride. Areas under the curve and the absorptivity values at the selected wavelength ranges were used for calculating the concentration of cyclopentolate hydrochloride using equation (5) and phenylephrine hydrochloride using equation (6) mentioned under "2.1".

For Q-analysis method: The absorbance values of cyclopentolate hydrochloride and phenylephrine hydrochloride were measured at 260 nm (λ_{iso}) and 273 nm (λ_{max} of phenylephrine hydrochloride) and the calibration graphs were constructed. The absorptivity values for each component at the selected wavelengths were used to calculate the concentration of cyclopentolate hydrochloride using equation (8) and phenylephrine hydrochloride using equation (9) mentioned under "2.2".

For bivariate method: The absorbance was measured at 255 and 270 nm and then the corresponding regression equations were computed at the selected wavelengths for both drugs. The obtained slopes and intercepts values were used for calculating the concentration of cyclopentolate hydrochloride using equations (3) and phenylephrine hydrochloride (4) mentioned under **"2.3**".

Application to laboratory prepared mixtures

The general procedure was repeated for each method using aliquots of cyclopentolate hydrochloride standard solution (1 mg/ml)

containing (0.1-0.6 mg) with aliquots of phenylephrine hydrochloride standard solution (1 mg/ml) containing (0.2-1.2 mg) and each drug concentrations were calculated.

Application to pharmaceutical formulation:

Contents of 5 **Cyclophrine**[®] eye drops were mixed well. 1 ml of the mixture containing 10 mg of cyclopentolate hydrochloride and 100 mg of phenylephrine hydrochloride was transferred into 100-ml volumetric flask then enriching technique was applied by addition of 40 mg of authentic cyclopentolate hydrochloride into the 100-ml volumetric flask and the volume was completed to 100 ml with methanol to obtain a stock solution labeled to contain 0.5 mg/ml of cyclopentolate hydrochloride and 1 mg/ml of phenylephrine hydrochloride [29]. Repeat the general procedure for each method using aliquots covering the working concentration range and determine the content of the eye drops.

RESULTS AND DISCUSSION

In the present study, three different spectrophotometric methods were applied for the for simultaneous determination of cyclopentolate hydrochloride and phenylephrine hydrochloride in their binary mixture without previous separation. These methods were applied to pharmaceutical preparation using enriching technique [29] by addition of authentic cyclopentolate hydrochloride to the pharmaceutical preparation, because the concentration of cyclopentolate hydrochloride is very low and practically does not reach the lower limit of concentration range in Beer's law.

Spectral characteristics and optimization of experimental conditions

The zero-order absorption spectra of cyclopentolate hydrochloride and phenylephrine hydrochloride, as shown in **figure (3)**, show severe overlap, which does not permit direct determination of the drugs in their binary mixture.




Fig. 3: Zero order absorption spectra of cyclopentolate hydrochloride, $100 \ \mu g/ml$ (___) and phenylephrine hydrochloride, $100 \ \mu g/ml$ (___) in methanol.

For area under the curve method, the area under the curves for cyclopentolate hydrochloride and phenylephrine hydrochloride were recorded over the ranges of (255-260) and (271-275) nm as shown in figure (4) for cyclopentolate hydrochloride and figure (5) for phenylephrine hydrochloride. The calibration graphs that relate the measured areas under the curve to the concentration of each component in μ g/ml were constructed and the regression equations were computed. The absorptivity values and areas under the curve for each component at the selected wavelength ranges were used to calculate the concentration of cyclopentolate hydrochloride using equation (5) and phenylephrine hydrochloride using equation (6) mentioned under "**2.1**". To choose the optimum wavelength ranges were selected using the general procedure under "**2.1**".




Fig. 4 : Zero order absorption spectrum of cyclopentolate hydrochloride (100 μ g/ml) showing area under the curve over the ranges (255-260) and (271-275) nm.




Fig. 5: Zero order absorption spectrum of phenylephrine hydrochloride (100 μ g/ml) showing area under the curve over the ranges (255-260) and (271-275) nm.

For Q-analysis method, the absorption spectra of 100 µg/ml of cyclopentolate hydrochloride, 100 µg/ml of phenylephrine hydrochloride, and a mixture containing equal concentration of them (50 µg/ml of each) showed isoabsorptive point at 260 nm, as shown in **figure (6)**. The spectra show also isoabsorptive point at 232.4 nm which was not involved in the method due to the low sensitivity at this wavelength. The absorbance values were measured at 273 nm (λ_{max} for phenylephrine hydrochloride) and 260 nm (λ_{iso}) in the range of 10-130 µg/ml for both drugs. Absorptivity values were determined for both cyclopentolate hydrochloride and phenylephrine hydrochloride. The values and the absorbance ratio were used to calculate the concentration of cyclopentolate hydrochloride and phenylephrine hydrochloride in their binary mixture using equations (8) and (9) mentioned under **"2.2"**, respectively.




Fig. 6: Zero-order absorption spectra of cyclopentolate hydrochloride 100 μg/ml (____), phenylephrine hydrochloride 100 μg/ml (____) and their mixture 50 μg/ml of each (....).

For bivariate method, In order to apply the method in the resolution of cyclopentolate hydrochloride and phenylephrine hydrochloride in their mixture, the absorbance of the two components individually at seven different wavelengths was recorded in the region of overlap; 245, 250, 255, 260, 265, 270 and 275 nm. The calibration curves equations and their respective linear regression coefficients were obtained directly with the aim of ensuring that: there was a linear relationship between the absorbance and the corresponding concentration. All of the calibration curves at the selected wavelengths showed a satisfactory linear regression coefficient (r > 0.9987). According to Kaiser method, the slope values of the linear regression equations for both drugs at the selected wavelengths were used to calculate the sensitivity matrices (K) to find out the optimum pair of wavelengths at which the binary mixture was recorded. It was found that; the slopes at 255 and 270 nm gave the maximum value of K table (1) and thus chosen for the analysis.

Table 1: The absolute values of the sensitivity matrix determinates calculated according to Kaiser's method ($k \times 10^5$) for the mixture of cyclopentolate hydrochloride and phenylephrine hydrochloride:

λ/ λ	24 5	250	255	260	265	270	275
24	0	12.5	246.3	903.4	1538.5	1982.6	1923.8
5	0	7	5	6	9	6	7
25		0	262.0	926.9	1570.8	1705.5	1652.9
0		0	5	8	1	1	1
25			0	665.9	1289.1	2021.9	1962.0
5			0	4	5	3	8
26				0	562.42	887.14	853.63
0				0	502.42	007.14	033.03
26					0	276.56	256.72
5					0	270.30	230.72
27						0	15.83
0						0	15.05
27							0
5							U

Methods validation

Validations of the proposed methods were assessed as per the ICH guidelines [30].

Linearity and range

Calibration graphs were constructed by repeating the general procedure for each method. The regression plots were found to be linear over the range of 10-130 μ g/ml for both drugs. The yielded statistical results are summarized in **table (2)**.

Limits of detection and quantitation

The limits of detection (LOD) and the limits of quantitation (LOQ) were calculated according to ICH guidelines from the following equations:

Where σ is the residual standard deviation of a regression line and S is the slope of the calibration curve. LOD and LOQ values were mentioned in table (2) and indicate good sensitivity of the methods.

Accuracy and precision

Accuracy and precision of the method were determined by applying the proposed procedure for determination of three different concentrations of each drug (30, 70 and 110 μ g/ml), each in triplicate, in pure form in the same day (intra-day) and in three successive days (inter-day), then the accuracy as percent recovery (%R) and precision as percent relative standard deviation (%RSD) were calculated and results are listed in table (2).

Accuracy of the method was also determined by applying the standard addition technique where the general procedure of each method was repeated using aliquots of standard solutions (1 mg/ml) of each drug containing $(100:200 \ \mu\text{g})$, $(110:220 \ \mu\text{g})$, $(120:240 \ \mu\text{g})$ and $(130:260 \ \mu\text{g})$ of cyclopentolate hydrochloride and

phenylephrine hydrochloride respectively with already analyzed aliquot of Cyclophrine[®] eye drops containing (0.5:1 mg), then the percent recovery (%R) of pure added concentrations were calculated and results are listed in table (3). From these data the methods show high accuracy and precision.

Specificity

The specificity of the proposed methods was assured by applying it to laboratory prepared mixtures of cyclopentolate hydrochloride and phenylephrine hydrochloride. The results were listed in table (4).

Table 2: Regression and validation data for the determination of cyclopentolate hydrochloride and phenylephrine hydrochloride by the proposed methods:

Parameters	Area under the curve		Q-analysis		Bivariate		
Parameters	CLO	PHE	CLO	PHE	CLO	PHE	
Wavelength (nm)	(255-260) & (271-2)	75)	260 & 273		255 & 270		
Linearity range (µg/ml)	10-130		10-130		10-130		
LOD (µg/ml)	2.685	2.581	2.483	2.333	2.048	2.236	
LOQ (µg/ml)	8.137	7.821	7.525	7.069	6.205	6.776	
Regression Equation	y = 0.0256 x + 0.0130 & y = 0.0097 x + 0.0083	0.0257 &	y = 0.0049 x + 0.0071 & y = 0.0025 x + 0.0019	y = 0.0051 x + 0.0014 & y = 0.0115 x + 0.0087	y = 0.0053 x + 0.0040 & y = 0.0030 x + 0.0054	y = 0.0029 x + 0.0053 & y = 0.0106 x + 0.0080	
Correlation coefficient (r)	0.9997 & 0.9996	0.9997 & 0.9997	0.9997 & 0.9997	0.9997 & 0.9997	0.9998 & 0.9998	0.9997 & 0.9998	
Accuracy (% R) Precision (% RSD)	100.39	100.17	99.72	99.96	100.23	99.35	
- Repeatability ^a -Intermediate	1.176	1.141	0.976	0.959	1.509	1.178	
precision ^b	1.001	0.919	0.965	0.847	0.790	1.133	

^a Average of three concentrations of each drug (30, 70 and 110 µg/ml) repeated three times within the day. ^b Average of three concentrations of each drug (30, 70 and 110 µg/ml) repeated three times in three days.

 Table 3: Recovery study of cyclopentolate hydrochloride and phenylephrine hydrochloride by standard addition technique via the proposed methods in Cyclophrine® eye drops:

	Pharmaceutical	taken (Pharmaceutical	found	Pure	added	Pure Recovery (%)		
Drug	µg/ml)	taken ((μg/ml)	Iounu	(μg/ml)	auueu	Area under the curve	Q- analysis	Bivariate
e			50.46ª		10		99.24	100.41	101.05
lat ide	50		50.46 ^a 50.62 ^b		11		98.15	99.76	100.32
Cyclopentolate hydrochloride	50				12		101.07	99.23	99.49
			49.68 ^c		13		98.33	101.04	100.71
dro	Mean						99.20	100.11	100.39
hy C	% RSD						1.347	0.785	0.669
de			100 (2)		20		98.33	100.35	100.68
	100		100.63 ^a		22		100.21	99.69	101.89
lor bh	100		100.14 ^b		24		98.96	101.51	99.75
chler			99.22°		26		99.78	100.58	100.19
eny dro	Mean						99.32	100.53	100.63
Ph _i	% RSD						0.845	0.749	0.918

^a Average of five determinations using area under the curve method.^b Average of five determinations using Q-analysis method.^c Average of five determinations using bivariate method.

 Table 4 :Determination of cyclopentolate hydrochloride and phenylephrine hydrochloride in synthetic laboratory mixtures by the proposed methods:

Taken amount		Found Recove	ery (%)				
(µg/ml)		Area under th	e curve	Q-analysis		Bivariate	
CLO	PHE	CLO	PHE	CLO	PHE	CLO	PHE
10	20	100.77	99.05	99.39	98.76	100.52	98.61
20	40	98.12	99.83	100.02	101.24	100.64	101.67
30	60	99.91	98.70	99.46	99.82	101.35	99.73
40	80	101.35	99.34	100.18	98.91	98.97	100.22
50	100	100.83	101.42	101.09	100.85	99.13	100.47
60	120	98.57	100.93	99.53	100.36	100.12	101.12
10	100	101.96	101.65	98.96	101.87	101.29	101.35
Mean		100.22	100.13	99.80	100.26	100.29	100.45
% RSD		1.423	1.192	0.699	1.164	0.947	1.052

Pharmaceutical applications

The proposed methods were applied for the simultaneous determination of cyclopentolate hydrochloride and phenylephrine hydrochloride in **Cyclophrine**[®] eye drops using enriching technique

[29] by addition of authentic cyclopentolate hydrochloride to the pharmaceutical preparation, because the concentration of cyclopentolate hydrochloride is very low and practically does not reach the lower limit of concentration range in Beer's law. Satisfactory results were obtained in good agreement with the label claim, indicating no interference from excipients and additives. The obtained results were statistically compared to those obtained by the reported method^[23] indicating good accuracy and precision of the proposed methods for the analysis of the studied drugs in their

pharmaceutical dosage form, as shown in **table (4)**. No significant differences were found by applying student's *t*-test and *F*-test at 95 % confidence level.

Table 5: Determination of cyclopentolate hydrochloride and phenylephrine hydrochloride in Cyclophrine® eye drops by the proposed methods and the reported method:

Parameters	Area under the curve		Q-analysis		Bivariate		Reported method* [23]	
r al alletel s	CLO	PHE	CLO	PHE	CLO	PHE	CLO	PHE
Number of measurements	5	5	5	5	5	5	5	5
Mean % recovery	100.92	100.63	101.23	100.14	99.35	99.22	101.09	100.87
% RSD	0.984	0.676	0.614	1.568	1.487	1.444	0.823	1.069
Student's <i>t</i> -test**	0.300 (2.306)	0.425 (2.306)	0.297 (2.306)	0.855 (2.306)	2.294 (2.306)	2.066 (2.306)		
<i>F</i> -value**	1.425 (6.388)	2.513 (6.388)	1.794 (6.388)	2.123 (6.388)	3.156 (6.388)	1.766 (6.388)		

*Reported method is HPLC method using Waters Spherisorb ODS2 C_{18} column and 0.1% heptane-1-sulphonic acid sodium salt in methanol : water (80:20, v/v) as a mobile phase with 1 ml/min flow rate and UV detection at 210 nm. ** The values in parenthesis are tabulated values of "t" and "F" at (P = 0.05)

CONCLUSION

This study described the first spectrophotometric methods developed and applied for simultaneous determination of cyclopentolate hydrochloride and phenylephrine hydrochloride in their binary mixture without need of any pre-separation step or sophisticated techniques and instruments. The proposed methods are simple, sensitive, rapid and inexpensive, so they are good alternative to the other few reported methods and to the high-cost HPLC and TLC methods. The methods were validated according to the ICH guidelines and can be easily applied for quality control and routine analysis of the studied drugs in bulk powder and in their pharmaceutical preparation.

ACKNOWLEDGEMENT

None

CONFLICT OF INTEREST

The authors declare that they have no conflict of interest.

REFERENCES

- 1. British Pharmacopoeia 2013. Vol. 2. London, UK: The Stationery Office; 2012.
- 2. United States Pharmacopoeia 30 and National formulary 25. Rockville (MD): United State Pharmacopoeia Convention; 2007.
- 3. Sweetman S. Martindale: the complete drug reference. 36th ed. London: The Pharmaceutical Press; 2009.
- Mohamed GG, Rizk MS, Frag EYZ. Spectrophotometric determination of distigmine bromide, cyclopentolate HCl, diaveridine HCl and tetrahydrozoline HCl via charge transfer complex formation with TCNQ and TCNE reagents. Iranian J Pharm Res. 2015; 14(3):701-714.
- Rao KK, Reddy MN, Rao SS, Rao MB. Estimation of cyclopentolate hydrochloride from ophthalmic solutions. Indian J Pharm Sci. 2002; 64(2):161-162.
- Rizk MS, Abdel-Haleem FM. Plastic membrane electrodes for the determination of flavoxate hydrochloride and cyclopentolate hydrochloride. Electrochim Acta. 2010; 55(20):5592-5597.
- Andermann G, Richard A. Determination of cyclopentolate by capillary column gas-liquid chromatography. J Sep Sci. 1984; 7(3):144-146.
- Roy AK, Guillory JK. The kinetics and mechanism of the hydrolysis of cyclopentolate hydrochloride in alkaline solutions. Int J Pharmaceut. 1995; 120(2):169-178.
- Koshy KT, Mitchner H. Colorimetric determination of phenylephrine using 4-aminoantipyrine. J Pharm Sci. 1963; 52(8):802-803.
- Dessouky YM, El Rub LNG. Colorimetric determination of phenylephrine hydrochloride in pharmaceutical preparations. Analyst. 1976; 101(1206):717-719.
- 11. Othman NS, Fatah NTA. Spectrophotometric determination of phenylephrine hydrochloride by coupling with diazotized 2-aminobenzothiazole. J Raf Sci. 2009; 20(4):69-81.

- 12. Theia'a NA. Spectrophotometric assay of phenylephrine hydrochloride using 4-aminoantipyrine and copper (II). Pak J Anal Env Chem. 2010; 11(1):1-7.
- Savic I, Nikolic G, Bankovic V. Development and validation of spectrophotometric method for phenylephrine hydrochloride estimation in nasal drops formulations. Maced J Chem Chem En. 2008; 27(2):149-156.
- 14. Perlado JC, Zapardiel A, Bermejo E, Perez JA, Hernandez L. Determination of phenylephrine with a modified carbon paste electrode. Anal Chim Acta. 1995; 305(1-3):83-90.
- Yao L, Tang Y, Zeng W, Huang Z. An electrochemical sensor for phenylephrine based on molecular imprinting. Anal Sci. 2009; 25(9):1089-1093.
- 16. Qu S, Pei S, Zhang S. Electrochemical behavior and determination of phenylephrine at silicate nanotubes modified electrode. J Chin Chem Soc. 2013; 60(9):1181-1185.
- Li K, Zhu M, Zhang H, Zhao J. Electrochemical determination of phenylephrine hydrochloride based on graphene-Tio2 modified glassy carbon electrode. Int J Electrochem Sci. 2013; 8(1):4047-4054.
- Pourghobadi Z, Niazi A. Voltammetric study and determination of phenylephrine hydrochloride at INP-Nafion-modified CPE sensor employing differential pulse voltammetry. Orient J Chem. 2014; 30(1):219-227.
- Habibi B, Ayazi Z, Zalvand F. Electrochemical Behavior and Determination of Phenylephrine at the Multi-Walled Carbon Nanotubes/ionic Liquid Nanocomposite Modified Electrode in the Presence of Acetaminophen; Int J Nanosci Nanotechnol; 2017; 13(3):203-218.
- 20. Gupta VD, Parasrampuria J. Quantitation of phenylephrine hydrochloride in pharmaceutical dosage forms. Drug Dev Ind Pharm. 1987; 13(3):473-486.
- Gumbhir K, Mason WD. High-performance liquid chromatographic determination of phenylephrine and its conjugates in human plasma using solid-phase extraction and electrochemical detection. J Pharmaceut Biomed. 1996; 14(5):623-630.
- Marın A, Barbas C. LC/MS for the degradation profiling of cough-cold products under forced conditions. J Pharmaceut Biomed. 2004; 35(5):1035-1045.
- 23. Rezk MR, Fayed AS, Marzouk HM, Abbas SS. Chromatographic determination of cyclopentolate hydrochloride and phenylephrine hydrochloride in the presence of their potential degradation products. J AOAC Int. 2017; 100(2):434-444.
- Chaudhary J, Jain A, Saini V. Simultaneous estimation of multicomponent formulations by UV-Visible spectroscopy: An overview. Int Res J Pharm. 2011; 2(12):81-83.
- 25. Abdelwahab NS. Spectrophotometric methods for simultaneous determination of Carvedilol and Hydrochlorothiazide in combined dosage form. Arabian J Chem. 2011;5(2):10-15.
- Pernarowski M, Kneval AM, Christian JE. Application of Absorbancy Ratios to the Analysis of Pharmaceuticals I. J PharmSci.1960; 50:943-945.
- 27. Darwish HW, Hassan SA, Salem MY, El-Zeany BA. Three different methods for determination of binary mixture of amlodipine and atorvastatin using dual wavelength

spectrophotometry. Spectrochim Acta A Mol Biomol Spectrosc. 2013;104:70-76.

- 28. Mossart DL, Vandeginste BG, Deming SN, Michotte Y, Kaufman L. Chemometrics: a text book. Amsterdam: Elsevier; 1988;124.
- 29. Abou-elkheir A, Saleh HM, El-Henawee MM, Ghareeb BS. Spectrophotometric determination of miconazole nitrate and

betamethasone valerate in bulk powder and in topical cream.Indo American J Pharm Res. 2014; 4(11):5507-5519.

30. International Conference on Harmonization, ICH Harmonised Tripartite Guideline. Validation of analytical procedure: text and methodology, Q2 (R1). Geneva: International Conference on Harm-onization; 2005.